FRIDAY 19 OCTOBER 2018

09:30 - 10:30 TYPE: CONTROVERSY SESSION

Title: Will CAR T cell therapy replace allogenic transplantation in lymphoma?
Hall A1 – Room 15 Chair(s): Martin Dreyling, DE
09:30 - 09:40 Introduction and 1st vote, M. Dreyling, DE
09:40 - 10:00 Yes, M. Subklewe, DE
10:00 - 10:20 No, D. Caballero, ES
10:20 - 10:30 2nd vote and conclusions, M. Dreyling, DE

11:00 - 12:30 TYPE: SPECIAL SYMPOSIUM

Title: How to balance efficacy and toxicity in Hodgkin’s Lymphoma
Hall B4 – Room 19 Chair(s): John Radford, GB; Simonetta Viviani, IT
11:00 - 11:05 Introduction, J. Radford, GB
11:05 - 11:25 Late toxicities, F. van Leeuwen, NL
11:25 - 11:45 Limited disease, J. Radford, GB
11:45 - 12:05 Advanced disease, D. Eichenauer, DE
12:05 - 12:25 Treatment of relapsed disease with novel agents, S. Viviani, IT
12:25 - 12:30 Conclusions and perspectives, S. Viviani, IT

12:00 - 13:20 TYPE: OPENING SESSION

Title: Opening session and award lectures
Hall A2 - Room 18

14:00 - 15:30 TYPE: JOINT SYMPOSIUM

Title: ESMO-SIOPE: Multidisciplinary management of life-after-cancer issues in adolescent and young adult survivors: Medicine and beyond
Hall B3 - Room 22 Chair(s): Giannis Mountzios, GR; Daniel Stark, GB
14:00 - 14:05 Introduction, D. Stark, Yorkshire/GB
14:05 - 14:25 Fertility preservation, parenthood and sexual health in AYA cancer survivors, F. Peccatori, IT
14:25 - 14:45 Late cardiovascular toxicity of anti-cancer treatment in adolescents and young adults, K. Rugbjerg, DK
14:45 - 15:05 Going back to school or work after cancer diagnosis: Professional and social reintegration of AYA cancer survivors, P. Riis Olsen, DK
15:05 - 15:25 Psychosocial, nutritional and physical activity aspects of AYA cancer survivors, A. Stein, DE
15:25 - 15:30 Conclusions, G. Mountzios, Neo Psychiko/GR
Title: ESMO-Meaningful Clinical Benefit Scale in perspective  
ICM - Room 14c Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL  
14:00 - 14:05 Introduction  
14:05 - 14:30 Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value Frameworks Net Health Benefit Score  
14:30 - 14:55 ESMO-MCBS v1.1 applied in haematological diseases  
14:55 - 15:20 How to help countries priorities their cancer systemic therapies – report from the WHO  
15:20 - 15:30 Conclusions

---

Title: Knowledge is power: Educating patients and advocates  
ICM - Room 5 Chair(s): Jan Geissler, CH; Bettina Ryll, SE  
14:30 - 14:45 Welcome to ESMO2018, B. Ryll1, J. Tabernero2; 1SE, 2ES  
14:45 - 15:05 Reaching patients: The podcast experience, F. Johansson, Sweden/SE  
15:25 - 15:45 The CML ECABs: Educating for excellence, J. Geissler, CH

---

Title: ESMO-ASCO Joint Symposium: Precision medicine and accessibility  
Hall A1 – Room 16 Chair(s): Josep Tabernero, ES; Monica Bertagnolli, US  
16:00 - 16:05 Introduction  
16:05 - 16:25 Basket studies and rapid development in precision oncology, A. Drilon, NY/US  
16:25 - 16:45 The European regulator’s point of view, F. Pignatti, GB  
16:45 - 17:05 The potential role of conditional approvals, P.G. Casali, IT  
17:05 - 17:25 The US regulator’s point of view, G. Blumenthal, MD/US  
17:25 - 17:30 Conclusions

---

Title: Toxicities from specific agents  
ICM - Room 14b Chair(s): Inge-Marie Svane, DK; Fiona Thistlethwaite, GB  
16:00 - 16:05 Introduction, I.-M. Svane, DK  
16:05 - 16:25 Acute and chronic toxicities, P. Ascierto, IT  
16:25 - 16:45 TILS therapy, I.-M. Svane, DK  
16:45 - 17:05 TCR and CAR in haematological malignancies, J. Svoboda, US  
17:05 - 17:25 TCR and CAR in solid tumours, F. Thistlethwaite, GB  
17:25 - 17:30 Conclusions and perspectives, F. Thistlethwaite, GB
Title: Best integration of supportive and palliative care in the continuum of care
Hall B3 - Room 22 Chair(s): Karin Jordan, DE; Stein Kaasa, NO
16:00 - 16:05 Introduction, K. Jordan, DE
16:05 - 16:25 Highlights of the Lancet Oncology commission paper: Integration of oncology and palliative care, S. Kaasa, NO
16:25 - 16:45 Insights of the ESMO position paper on supportive and palliative care, K. Jordan, DE
16:45 - 17:05 Palliative care in main stream oncology, how and how much: A Canadian Perspective, C. Zimmermann, CA
17:05 - 17:25 The place and content of Supportive and palliative care in a comprehensive cancer center in Europe
17:25 - 17:30 Conclusions, S. Kaasa, NO

Title: Immunotherapy check points: What to tell your patients
ICM - Room 5 Chair(s): John Haanen, NL; Bettina Ryll, SE
16:00 - 16:20 Introduction, B. Ryll, SE
16:20 - 16:40 How long should we treat patients?, J. Haanen, NL
16:40 - 17:00 Side effects, J. Larkin, GB
17:00 - 17:30 Q&A

Title: Life after cancer
ICM - Room 5 Chair(s): Isabelle Lebrocquy, NL; Tanja Spanic, SI
17:45 - 18:00 When is a cancer patient cured?, L. Dal Maso, IT
18:00 - 18:15 What is Europe doing in return to work?, A. de Boer, NL
18:15 - 18:30 The right to be forgotten, A. Dumas, FR
18:30 - 18:45 Advocating for survivors’ rights, I. Lebrocquy, NL
18:45 - 19:15 Q&A
SATURDAY 20 OCTOBER 2018

08:00 - 09:00 TYPE: CHALLENGE YOUR EXPERT (CYE) SESSION

Title: Skin toxicity of anticancer treatments: How to diagnose, how to treat
Hall B3 – Room 23 Chair(s): Petra Feyer, DE
08:00 - 08:10 Skin toxicity of anticancer treatments: How to diagnose, how to treat V. Sibaud, Haute-Garonne/FR
08:10 - 09:00 Discussion led by P. Feyer, DE

09:15 - 10:45 TYPE: JOINT SYMPOSIUM

Title: ESMO-DGHO Joint Symposium: Access to anti-cancer drugs
Hall B3 – Room 23 Chair(s): Alexandru Eniu, RO; Volker Heinemann, DE
09:15 - 09:20 Introduction
09:20 - 09:40 The shortage of essential oncology drugs, A. Eniu, RO
09:40 - 10:00 Access to innovative/expensive drugs, R. Sullivan, GB
10:00 - 10:20 What is a fair price?, C. Bokemeyer, DE
10:20 - 10:40 Strategies in Germany, B. Woermann, DE
10:40 - 10:45 Conclusions

09:15 - 10:30 TYPE: POSTER DISCUSSION SESSION

Title: Poster Discussion session - Public Health
Hall B4 - Room 19 Chair(s): Fredericus Eskens, NL

09:15 - 09:15 1561PD - Variation in Oncology Drug Approvals in Canada, the United States and Europe, O. Khan1, N. Samuel1, S. Verma2; 1CA, 2Alberta/CA

09:35 - 09:35 1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA), C. Molto Valiente1, M. Borrell1, A. OcanA Fernandez1, A. Templeton2, L. del Carpio1, J. Del Paggio3, A. Barnadas1, C. Booth4, A. Tibau1, E. Amir4; 1ES, 2CH, 3CA, 4ON/CA

09:35 - 09:35 1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval, M. Borrell Puy1, C. Molto Valiente1, K. Vokinger2, T. Hwang3, A. OcanA Fernandez1, A. Templeton2, B. Seruga4, I. Gich Saladich1, A. Barnadas1, E. Amir5, A. Tibau1; 1ES, 2CH, 3US, 4SI, 5ON/CA

09:35 - 09:35 1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs C. Molto Valiente1, M. Borrell1, T. Hwang2, I. Gich Saladich1, A. Barnadas1, E. Amir3, A. Kesselheim4, A. Tibau1; 1ES, 2US, 3ON/CA, 4MA/US
09:35 - 09:35 **1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores**, U. Janzic, L. Knez, A. Janzic, T. Cufer, SI

---

**09:15 - 10:45 TYPE: EONS SESSION**

**Title: EONS-ONS Session: Innovation in cancer nursing and leadership**

**Hall B4 – Room 24** Chair(s): Lena Sharp, SE

09:15 - 09:25 **Introduction and welcome**

L. Sharp1, D. Kelly2, K. Paradies3; 1SE, 2GB, 3DE

09:25 - 09:35 **Recognizing European Cancer Nursing, RECaN: Results from systematic review and meta-analyses (RECaN Phase 1)** D. Kelly, GB

09:35 - 09:45 **Results from case studies from four contrasting countries in Europe (RECaN Phase 2)** L. Sharp, SE

09:45 - 09:55 **Promoting cancer nursing across Europe (RECaN Phase 2 qualitative insights and looking ahead to phase 3)** D. Kelly, GB

09:55 - 10:25 **Supporting cancer nursing leadership development: The USA experience**

L. Fennimore, US

10:25 - 10:45 **Discussion**

---

**09:30 - 10:30 TYPE: CONTROVERSY SESSION**

**Title: Will CAR T cell therapy replace allogenic transplantation in lymphoma?**

**Hall A1 – Room 15** Chair(s): Martin Dreyling, DE

09:30 - 09:40 **Introduction and 1st vote**, M. Dreyling, DE

09:40 - 10:00 **Yes**, M. Subklewe, DE

10:00 - 10:20 **No**, D. Caballero, ES

10:20 - 10:30 **2nd vote and conclusions**, M. Dreyling, DE

---

**11:00 - 12:30 TYPE: SPECIAL SYMPOSIUM**

**Title: How to balance efficacy and toxicity in Hodgkin’s Lymphoma**

**Hall B4 – Room 19** Chair(s): John Radford, GB; Simonetta Viviani, IT

11:00 - 11:05 **Introduction**, J. Radford, GB

11:05 - 11:25 **Late toxicities**, F. van Leeuwen, NL

11:25 - 11:45 **Limited disease**, J. Radford, GB

11:45 - 12:05 **Advanced disease**, D. Eichenauer, DE

12:05 - 12:25 **Treatment of relapsed disease with novel agents**, S. Viviani, IT

12:25 - 12:30 **Conclusions and perspectives**, S. Viviani, IT

---

**11:00 - 11:45 TYPE: YOUNG ONCOLOGIST SESSION**

**Title: YO Brunch 1: Fertility and pregnancy in cancer**

**ICM - Room 14c** Chair(s): Matteo Lambertini, BE; Claudia Cardone, IT

11:00 - 11:45 **Fertility and pregnancy in cancer**, F. Peccatori, IT
Title: EONS Poster display
Hall B4 - Room 24
12:00 - 12:00 CN5 - Patients - power sources for cancer nurses, C. Beisel, DE

12:00 - 12:00 CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses – patient-reported evaluation. B. Westman, H. Ullgren, L. Sharp; SE

12:00 - 12:00 CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method, H. Ullgren, SE

12:00 - 12:00 CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study, S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR

12:00 - 12:00 CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease, J. De Munter, S. De Wilde, M. Quaghebeur; BE

12:00 - 12:00 CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital, A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES

12:00 - 12:00 CN18 - Are there differences between nurses’ and patients’ perceptions of cancer patients’ quality of life in Greece?, M. Lavdaniti, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. Zioga, K. MARMARA, E. Fradelos; GR

12:00 - 12:00 CN31 - Comparing nurses’ and patients’ research priorities in cancer care: A mixed methods systematic review, L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT

12:00 - 12:00 CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network, K. Dieperink, M. Kjerholt, P. Riis Olsen; DK

12:00 - 12:00 CN39 - Development and implementation of national guidelines on lifestyle issues and cancer - Report from an on-going quality improvement project, K. Vuollet Karlsson, C. Landegren, B. Westman; SE

12:00 - 12:00 CN47 - Patients’ interpretations and experiences of participation in cancer care J. Jackson, J. Rundgren; SE

12:00 - 12:00 CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care, J. De Munter, P. Crombez; BE
12:00 - 12:00 **CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre**, M. Foulkes, GB

12:00 - 12:00 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**, C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protopiros, E. Patiraki; GR

12:00 - 12:00 **CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study**, D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT

12:00 - 12:00 **CN61 - “It may not affect you” -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.**, M. Tanay, J. Armes; GB

---

**12:30 - 13:30 TYPE: POSTER DISPLAY SESSION**

---

**Title: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research**

Hall A3 - Poster Area Networking Hub


12:30 - 12:30 **1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death**, S. Clara1, A. Lok1, T. Gastinne1, B. Mahé1, V. Dubruille1, N. Blin1, S. Howlett2, A. Tabah2,P. Arnaud3, A. Moreau1, P. Moreau1, C. Leux1, S. Le Gouill1; 1FR, 2NJ/US, 3CEDEX 18/FR


12:30 - 12:30 **1021P - Long term treatment outcome of patients with refractory or relapsed Hodgkin’s lymphoma in the anthracycline era: a single-center intention-to-treat analysis**

T. Bogatyreva, A. Terekhova, S. Shklyaev, V. Pavlov, N. Falaleeva; RU


12:30 - 12:30 **1030P - Poor outcome of double-protein expressor diffuse large B-cell lymphoma**, E. Kharchenko, T. Semiglazova, A. Artemeva, V. Kushnarev, P. Shilo; RU

12:30 - 12:30 **1032P** - The impact of serum microRNA-21 on outcome of diffuse large B-cell lymphoma patients

12:30 - 12:30 **1038P** - PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin Lymphoma., T. Skrypets1, O. Novosad1, I. Pastushenko1, T. Kadnikova1, O. Gorbach1, Y. Kmetyuk1, O. Karpova1, L. Mykhalska1, E. Lukjanec1, V. Kozlov1, N. Novikov1, O. Oliinichenko1, N. Kostiukova1, O. Tkachenko1, O. Karnabeda2, V. Stratienko1, I. Kriachok1; 1UA, 2Kiev region/UA

12:30 - 12:30 **1034P** - A Prospective Multicenter Study of Primary Breast Lymphoma in the rituximab era: prognostic implication of beta 2 microglobulin and interlukin-6 & interlukin-10
L. Ezz Elarab1, E. Hamada1, A. Mostafa1, A. Saber1, M. Abdel-Gawad1, R. Haggag2, H. Darwish1, S. Elhassanin1, M. Swellam1; 1EG, 2ElSharkia/EG

12:30 - 12:30 **1036P** - Inmunohistochemical (IHQ) classification of DLBCL into CGB and non-CGB subtypes to predict survival after chemoimmunotherapy, at the Virgen de la Victoria University Hospital
L. Galvez Carvajal, C. Quero Blanco, M. Robles Lasarte, I. Moreno Perez, L. Vicioso, I. Ramos Garcia, C. Bandera Lopez, J. Baena Espinar, C. Ithurbisquy, E. Alba; ES

---

**12:30 - 14:30 TYPE: PATIENT ADVOCACY TRACK**

**Title:** Pillars of an effective healthcare system in Europe  
**ICM - Room 5** Chair(s): Ananda Plate, BE; Vlad Voiculescu, RO

12:30 - 12:45 **Key components of a well-functioning healthcare system,** W. Quentin, DE

12:45 - 13:00 **Measuring performance of healthcare systems: The Euro Health Consumer Index,** B. Cebolla Garrofé, FR

13:00 - 13:15 **Special focus on healthcare in CEE,** V. Voiculescu, RO

13:15 - 13:30 **Civic participation: How citizens shape the society they live in,** G. Moro, IT

13:30 - 14:00 **Discussion**

---

**14:45 - 16:15 TYPE: SPECIAL SESSION**

**Title:** Technologies of the future  
**Hall A1 - Room 16** Chair(s): Alex A. Adjei, US; Udai Banerji, GB

14:45 - 15:15 **CRISPR,** R. Bernards, NL

15:15 - 15:45 **CAR T cells,** M. Sadelain, US

15:45 - 16:15 **Oncolytic viruses,** E. Galanis, MN/US
Title: Patient safety
Hall B4 - Room 24 Chair(s): Cristina Lacerda, GB
14:45 - 15:00 Patient safety as a current concern for health systems in Europe, D. Schwappach, CH
15:00 - 15:15 Cancer’s a risky business: Risk assessment in oncology nursing, J. Richmond, IE
15:15 - 15:30 Safety in the era of oral chemotherapy, L. Iacorossi, IT
15:30 - 15:45 Safety outside of cancer centres: The rise of oral chemotherapy and the safety needs of patients, C. Oakley, GB
15:45 - 16:15 Discussion

Title: The way to assure sustainable, accessible and affordable cancer care within National Cancer Control Plans (NCCP)
ICM – Room 14a Chair(s): Giuseppe Curigliano, IT; Lisa Stevens, US
14:45 - 14:50 Introduction, L. Stevens, US
14:50 - 15:05 To have an NCCP or not: That is issue and where should we begin?, A. Eniu, RO
15:05 - 15:20 Profile from Central Europe – Czech Republic, T. Svoboda, Plzen/CZ
15:50 - 16:15 Interactive Q&A/Wrap up, G. Curigliano, IT

Title: Cancer prevention
ICM - Room 5 Chair(s): Gilberto Morgan, SE; Fredrik Johansson, SE
18:00 - 18:15 Why we are losing the war on cancer, C. Leaf, US
18:15 - 18:30 Tobacco control: Saving lives and driving development, G. Morgan, SE
18:30 - 18:45 Behavioural aspects of health-related prevention measures, A. Leppänen, SE
18:45 - 19:00 Cancer awareness and screening: The challenges, J. Gore-Booth, Wiltshire/GB
19:00 - 19:30 Discussion
SUNDAY 21 OCTOBER 2019

08:00 - 09:00 TYPE: CHALLENGE YOUR EXPERT (CYE) SESSION

Title: Follicular and other indolent lymphomas
ICM - Room 14a Chair(s): Martin Dreyling, DE
08:00 - 08:10 Follicular and other indolent lymphomas, M. Ghielmini, CH
08:10 - 09:00 Discussion led by, M. Dreyling, DE

09:30 - 10:30 TYPE: SPECIAL SESSION

Title: Integration of immunotherapy with disease entities
Hall A1 - Room 16 Chair(s): Ulrich Keilholz, DE
10:10 - 10:30 Lymphoma, C. Arber Barth, TX/CH

09:30 - 10:30 TYPE: SPECIAL SESSION

Title: Using population data evidence to support policy decisions in cancer
Hall B3 – Room 22 Chair(s): Andrew Briggs, GB; Bengt Jönsson, SE
09:30 - 09:45 The role of evidence in alternative frameworks for the valuation of oncology
Treatments B. Jönsson, SE
09:45 - 10:00 Using real world data for decision-making in R&D and health technology assessment
S. Khozin, US
10:00 - 10:15 Using RWE to identify gaps in the provision of effective – and cost-effective – care
A. Briggs, GB
10:15 - 10:30 Discussion

09:30 - 10:30 TYPE: MULTIDISCIPLINARY INTERACTIVE SESSIONS

Title: Dissecting mediastinal grey zone lymphomas
Hall B3 - Room 20 Chair(s): Maurizio Martelli, IT
09:30 - 09:35 Case presentation, M. Martelli, IT
09:35 - 09:45 The pathologist’s perspective, T. Molina, FR
09:45 - 09:55 The haematologist’s perspective, M. Martelli, IT
09:55 - 10:05 The radiation oncologist’s perspective
10:05 - 10:35 Discussion

10:45 - 12:45 TYPE: CLINICAL PRACTICE GUIDELINES

Title: ESMO Clinical Practice Guidelines 1
Hall A1 - Room 15 Chair(s): George Pentheroudakis, GR
10:45 - 10:55 Introduction, G. Pentheroudakis, GR
11:30 - 11:40 Mantle cell lymphoma, M. Jerkeman, SE
11:40 - 11:50 Discussant, M. Dreyling, DE
Relevant sessions for Lymphoma Patient Advocates

Title: Proffered paper session - Haematological malignancies
Hall B4 - Room 19 Chair(s): Marco Ladetto, IT; Maria-Victoria Mateos, ES


11:15 - 11:30 1005O - A Revised International Prognostic Score System for Waldenström’s Macroglobulinemia, M. Gavriatopoulou1, E. Kastritis1, P. Morel2, A. Duhamel3, E. Durot3, A. Symeonidis1, K. Laribi3, E. Hatjiharisis1, L. Ysebaert3, A. Vassou1, N. Giannakoulas1, G. Merlini4, P. Repousis1, M. Varettoni3, E. Michalis1, B. Hivert3, M. Michalis5, V. Leblond3, M. Dimopoulos1; 1GR, 2Pas de Calais/FR, 3FR, 4IT, 5CY

11:30 - 11:45 1006O - Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: combined analysis from phase I and II studies
P. Zinzani1, A. Santoro2, L. Mollica3, G. Follows4, K. Bouabdallah5, F. Morschhauser5, A. Patnaik6, L. Huang6, F. Hiemeyer7, A. Benson8, I. Genvresse7, J. Garcia-Vargas8, B. Childs9, M. Dreyling7; 1IT, 2(MI)/IT, 3CA, 4GB, 5FR, 6US, 7DE, 8NJ/US, 9New York/US

12:00 - 13:00 TYPE: POSTER DISPLAY SESSION

Title: EONS Poster display
Hall B4 - Room 24

12:00 - 12:00 CN5 - Patients - power sources for cancer nurses, C. Beisel, DE

12:00 - 12:00 CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital. J. Duncan1, V. Michalarea2, T. Coyne1, J. Thomas1, D. Cunningham1; 1GB, 2Surrey/GB

12:30 - 12:30 67P - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin’s lymphoma or advanced solid tumors

12:30 - 12:30 1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death, S. Clara1, A. Lok1, T. Gastinne1, B. Mahé1, V. Dubruille1, N. Blin1, S. Howlett2, A. Tabah2, P. Arnaud3, A. Moreau1, P. Moreau1, C. Leux1, S. Le Gouill1; 1FR, 2NJ/US, 3CEDEX 18/FR

12:30 - 12:30 **1021P** - Long term treatment outcome of patients with refractory or relapsed Hodgkin’s lymphoma in the anthracycline era: a single-center intention-to-treat Analysis, T. Bogatyreva, A. Terekhova, S. Shklyaev, V. Pavlov, N. Falaleeva; RU


12:30 - 12:30 **1030P** - Poor outcome of double-protein expressor diffuse large B-cell lymphoma E. Kharchenko, T. Semiglazova, A. Artemeva, V. Kushnarev, P. Shilo; RU

---

**12:30 - 14:00 TYPE: PATIENT ADVOCACY TRACK**

**Title: The cancer drugs we need: Incentivising innovation in cancer**

ICM – Room 5 Chair(s): Bettina Ryll, SE

12:30 - 12:45 The entrepreneurial state
12:45 - 13:00 Innovating for public health, S. Garner, CH
13:00 - 13:15 Incentivising innovation, J. Scannell, GB
13:15 - 13:30 Patient advocate driving innovation
13:30 - 14:00 Discussion

---

**14:45 - 16:15 TYPE: EONS SESSION**

**Title: The essential elements of safety standards for systemic cancer therapies**

Hall B4 – Room 24 Chair(s): Theresa Wiseman, GB

14:45 - 15:00 The pharmacist’s perspective, K. Meier, DE
15:00 - 15:15 The oncologist’s perspective, F. Overkamp, DE
15:15 - 15:30 The nurse manager’s perspective, C. Lacerda, GB
15:30 - 15:45 The clinical nurse’s perspective, H. Titzer, AT
15:45 - 16:00 The patient’s perspective, M. Järvinen, FI
16:00 - 16:15 Discussion

---

**14:45 - 16:15 TYPE: SPECIAL SESSION**

**Title: Are there enough cancer services and oncologists in your country?**

ICM – Room 14a Chair(s): Alexandru Eniu, RO; André Ilbawi, CH

14:45 - 15:00 Introduction, A. Eniu, RO
14:50 - 15:10 Where does the world stand on global cancer control?, A. Ilbawi, CH
15:10 - 15:30 Tools that show how investing in cancer care pays off
15:30 - 15:50 How many patients can one oncologist care for?, D. Trapani, IT
15:50 - 16:10 **WHO-ESMO Workforce Survey: How can your country assure enough oncologists for the future?**, G. Curigliano, IT
16:10 - 16:15 **Conclusions**

----------------------------------------

**16:30 - 18:00 TYPE: EONS SESSION**

**Title: Improving communication in cancer nursing**
**Hall B4 - Room 24** Chair(s): Patrick Crombez, BE
16:30 - 16:50 **How to communicate well with people with advanced disease** E. Patiraki, GR
16:50 - 17:10 **Be silent, or say something better than silence** E. Masel, AT
17:10 - 17:30 **Dealing with impending death in young adult cancer patients: How to communicate and offer effective support in practice** M. Bisset, GB
17:30 - 18:00 **Discussion**

----------------------------------------

**16:30 - 17:45 TYPE: POSTER DISCUSSION SESSION**

**Title: Poster Discussion session – Haematological malignancies**
**Hall B3 – Room 21** Chair(s): Marion Subklewe, DE; Andres Ferreri, IT; Michele Ghielmini, CH

16:30 - 16:30 **1008PD - CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies.**, K. Lee1, K. Gowrishankar1, D. Gottlieb2, E. Blyth2, K. Micklethwaite2; 1AU, 2NSW/AU

16:55 - 16:55 **1010PD - ALK positive Anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring**, M. Kalinova, L. Krskova, M. Mrhalova, E. Kabickova, P. Riha, R. Kodet; CZ

16:55 - 16:55 **1011PD - Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.**, J. Sandoval-Sus1, S. Dalia2, R. Mhaskar3, J. Chavez1, A. Ausekar4, K. Purnapatre4, J. Scheiber4, L. Sokol1; 1FL/US, 2MO/US, 3US, 4DE

16:55 - 16:55 **1012PD - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice**, M. Dreyling1, G. Hess1, M. Woke2, G. Krekeler1; 1DE, 2NA


16:55 - 17:10 **Invited Discussant 1010PD, 1011PD, 1012PD and 1013PD**, A. Ferreri, IT

17:10 - 17:20 **Q&A led by Discussant**
17:20 - 17:20 **1014PD** - Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies, W. Jurczak1, S. Rule2, W. Townsend3, D. Tucker3, B. Sarholz4, J. Scheele4, J. Gribben3, P. Zinzani5; 1PL, 2Devon/GB, 3GB, 4DE, 5IT


17:20 - 17:20 **1016PD** - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRIZ2012), M. Kanno1, K. Miura1, Y. Masaki1, H. Tsujimura2, M. Iino1, J. Takizawa1, Y. Maeda1, K. Yamamoto1, S. Tamura1, A. Yoshida1, H. Yagi1, I. Yoshida1, K. Kitazume1, T. Masunari1, I. Choi1, Y. Kakinoki1, T. Yoshino1, S. Nakamura1, T. Yoshida1; 1JP, 2Chiba/JP

17:20 - 17:35 **Invited Discussant 1014PD, 1015PD and 1016PD**, M. Ghielmini, CH

17:35 - 17:45 **Q&A led by Discussant**

---

**Title:** Snake oil sold as science: How to protect patients from Pseudoscience

ICM – Room 5 Chair(s): Matthias Preusser, AT; Gilliosa Spurrier, FR

18:00 - 18:15 **Pseudoscience and having to destroy false hope: The oncologist’s perspective**
P. Wolter, BE

18:15 - 18:30 **Characteristics of pseudoscience**, E. Ernst, GB

18:30 - 18:45 **The responsibility of journalism in science reporting**, H. Scowcroft, GB

18:45 - 19:00 **Preventing pseudoscience on patient forums**, G. Spurrier, FR

19:00 - 19:30 **Discussion**

---

**Title:** ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Hall A1 – Room 16

18:30 - 18:35 **Introduction**

18:35 - 18:45 **Acceptance of oncology biosimilars in supportive care: a success story**

18:45 - 18:55 **Existing challenges for uptake of oncology biosimilars – ESMO survey results**

M. Vyas, CH

18:55 - 19:05 **In practice (UK): patients being switched from a biologic to a biosimilar - UK**

19:05 - 19:15 **One year on – state of play in the EU on oncology biosimilars**, M. Aitken, US

19:15 - 19:25 **Supplementary Protection Certificates & their potential impact on availability of biosimilars**

19:25 - 19:55 **Panel with industry representatives**

19:55 - 20:00 **Conclusion**
MONDAY 22 OCTOBER 2018

11:00 - 12:30 TYPE: SPECIAL SESSION

**Title: The changing scenario of drug registration**
**Hall B3 - Room 21**
11:00 - 11:05 Introduction
11:05 - 11:25 *Reasons for not lowering the bar for new drugs registration*, I. Tannock, Ontario/CA
11:25 - 11:45 *Accelerated / conditional approval as a new regular way of drug registration*
11:45 - 12:05 *Patients expectations from drug regulators: The view of the patient advocate* B. Ryll, SE
12:05 - 12:15 Conclusions

11:00 - 12:30 TYPE: SPECIAL SYMPOSIUM

**Title: Global surveillance of cancer survival: Impact on cancer control**
**Hall B3 – Room 20** Chair(s): Michel Coleman, GB
11:00 - 11:05 *Introduction: Global surveillance of cancer survival will stimulate policy and improve equity*, M. Coleman, GB
11:05 - 11:25 *Trends & inequalities in cancer survival world-wide: The latest results*, C. Allemani, GB
11:25 - 11:45 *Information for cancer patients, their families and care-givers: Improving outcomes in low- and middle-income countries*, S. Cowal, US
11:45 - 12:05 *Cancer survival comparisons as a tool to improve the quality of health care: The experience from OECD*, N. Klazinga, FR
12:05 - 12:25 *Delivering affordable cancer care in developed and developing countries* R. Sullivan, GB
12:25 - 12:30 Panel discussion

12:30 - 14:00 TYPE: PATIENT ADVOCACY TRACK

**Title: The Hans Keulen Memorial Debate**
**ICM - Room 5** Chair(s): Kathy Oliver, GB
12:30 - 12:40 *Introduction*, K. Oliver, GB
12:40 - 13:20 Debate
13:20 - 13:20 Debate: Team 1, A. Waldman1, M. Inderbitzin2; 1DE, 2CH
13:20 - 13:40 Debate: Team 2, F. Strasser1, A. Charalambous2; 1CH, 2CY
13:20 - 13:50 Discussion with the audience
13:50 - 14:00 Conclusions and take-home messages
Title: Affordability and sustainability of new cancer drugs
Hall B3 - Room 22 Chair(s): Carin Uyl-de Groot, NL; Fredericus Eskens, NL
16:30 - 16:55 The economics of innovative medicines, C. Uyl-de Groot, NL
16:55 - 17:20 The use of scales to determine the magnitude of benefit of drugs, E.G.E. de Vries, NL
17:20 - 17:45 Differential pricing across Europe: addressing needs of middle- and low income countries, Z. Kaló, HU
17:45 - 18:00 Discussion about the role of social media

Notes: